MARK A. GOLDSMITH - 01 Mar 2022 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role
President and Chief Executive Officer, Director
Signature
/s/ Jack Anders, as attorney-in fact for Mark A. Goldsmith
Issuer symbol
RVMD
Transactions as of
01 Mar 2022
Net transactions value
$0
Form type
4
Filing time
03 Mar 2022, 15:28:40 UTC
Previous filing
21 Dec 2021
Next filing
21 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Award $0 +104,000 +126% $0.000000 186,622 01 Mar 2022 Direct F4
holding RVMD Common Stock 37,032 01 Mar 2022 Trust F1
holding RVMD Common Stock 37,032 01 Mar 2022 Trust F2
holding RVMD Common Stock 266,506 01 Mar 2022 Trust F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVMD Stock Option (Right to Buy) Award $0 +363,000 $0.000000 363,000 01 Mar 2022 Common Stock 363,000 $18.56 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Held by Jonathan Henry Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011.
F2 Held by Rebecca Eve Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011.
F3 Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
F4 Includes 143,000 Restricted Stock Units.
F5 One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2022 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Remarks:

President and Chief Executive Officer